CardiologyVideo course2025
Heart in Diabetes Conference 2025 — three days of cardio-renal-metabolic medicine
The Heart in Diabetes Conference 2025, the ninth annual meeting, is recorded here as 72 videos across three days — close to 22 hours of teaching on where cardiology, nephrology and endocrinology meet. Resistant hypertension, CKD, hypercortisolism, sleep, MASLD, HFpEF, incretins and SGLT2 inhibitors, finerenone, ApoB and CETP inhibition, and obesity all get dedicated sessions, each block closing with a panel Q&A.
- 72videos
- 21 h 51 minof teaching
- 3conference days
What you’ll be able to do
- Work up and treat resistant hypertension and CKD with or without albuminuria
- Combine GLP-1 RAs, SGLT2 inhibitors and non-steroidal MRAs for heart and kidney protection
- Recognise the cardiometabolic effects of hypercortisolism, sleep disorders and MASLD
- Use ApoB and newer lipid therapies, including CETP inhibitors, in practice
- Manage obesity with heart failure while preserving lean mass
- Read the latest cardiovascular outcome trials critically
Inside the course
Day one: hypertension, kidney and the diabetes comorbidities
Resistant hypertension and CKD open the meeting, followed by three talks on cortisol, MASLD and MASH, two on sleep, prediabetes, diabetes and dementia, lung disease and older adults. Implementation science, women’s lipid and heart failure risk, and four late-breaking studies with a Circulation panel complete the 28-video day.
Day two: Heart in Diabetes Conference 2025 on heart failure and incretins
Heart failure epidemiology, diabetic cardiomyopathy, bromocriptine in peripartum cardiomyopathy and HFpEF management lead into three incretin lectures. Genetics of lipid disorders, HoFH, CETP inhibitors, ApoB targets and dual agonists follow, then CKM disease, finerenone, digital health, food-is-medicine and the ARISE-HF results.
Day three: complex cases, obesity and ASCVD
Case-based sessions on obesity with heart failure and the edema dilemma, the Lancet Commission on Obesity, lean-mass preservation, ACE inhibitors in the SGLT2 era, aldosterone, combination therapy in diabetic kidney disease, the latest AHA statistics and an update on outcome trials.
Built for
- CardiologistsThe metabolic and renal evidence now shaping cardiovascular prevention.
- EndocrinologistsHeart and kidney outcomes of modern diabetes and obesity drugs.
- NephrologistsCardio-renal protection and resistant hypertension in one programme.
Syllabus
Day 1 sessions 28 videos
- Epidemiology and Pathophysiology of Resistant Hypertension and CKD Treatment
- Management of Chronic Kidney Disease With or Without Albuminuria
- Emerging Approaches to the Treatment of Resistant Hypertension
- Case Presentation – Treatment Resistant Hypertension
- Cortisol – Impact on Endocrinology & Metabolism
- Cortisol’s Impact on the Kidney-BP-Bone
- Cardiovascular Implications of Hypercortisolism
- Panel Discussion and Q&A – Cortisol & Cardiorenalmetabolic Diseases
- MASLD and MASH – Pathophysiology, Diagnosis and Management
- Sleep Health: Implications for Obesity and Diabetes Risk
- Sleep and Cardiovascular Risk
- Panel Discussion and Q&A – Sleep Disorders in Cardiometabolism
- Prediabetes: What’s a Clinician to Do?
- Unraveling the Connection: Diabetes and Dementia
- Pulmonary Disorders in Diabetes – Implications for Heart Disease
- Diabetes and Cardiovascular Disease in Older Adults
- Panel Discussion and Q&A – Diabetes Comorbidities
- Implementing Guideline-Directed Medical Therapy: Stakeholder-Identified Barriers and Facilitators
- Population Health Approaches to Accelerate the Prevention of CVD: Moving from Action to Impact
- Panel Discussion and Q&A – Implementation Science in Practice
- Dyslipidemia in Women Across a Lifetime Approach to Management
- Sex Hormones and Anthropometric Measures & Heart Failure Risk in Women
- Panel Discussion and Q&A – Women’s Health
- Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone or In Combination With SGLT2 Inhibitors in T2D
- Optimal Strategy for Heart Failure Screening Among Adults With Diabetes Without ASCVD – A Pooled Cohort Analysis
- Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With T2D and CKD
- Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Chronic Kidney Disease
- Panel Discussion and Q&A – Circulation
Day 2 sessions 27 videos
- Current Trends in Epidemiology of Heart Failure – USA
- Diabetic Cardiomyopathy: Mechanisms and Future Directions
- Bromocriptine in the Treatment of Peripartum Cardiomyopathy: Is It Ready for Prime Time?
- Proper Medical Management of HFpEF in 2025
- Panel Discussion and Q&A – Heart Failure: The Now & The New
- GLP1-RA, Obesity & Diabetes: Mechanisms of Cardiovascular Protection
- Cardio-Kidney Protection With Incretin Therapies
- Incretins: Today and Tomorrow
- Panel Discussion and Q&A – Current & Future Role of Incretin Therapy
- Diabetes and Cardiovascular Disease: The Evolution of CV Outcomes Assessment of Antihyperglycemic Medications
- My Personal Journey to HoFH Diagnosis
- From Rare to the Very Common – Role of Genetics in Lipid Disorders
- CETPi – Where Might They Fit Into Clinical Practice
- Using ApoB in Clinical Practice – From Risk Assessment to Treatment Targets
- Obesity and Dyslipidemia – Can We Finally Break the Cycle With Dual Agonists
- The Epidemiology and Pathophysiology of Cardio-Kidney-Metabolic Diseases
- Unmet Needs in CKD in T1D and Challenges in CKD Beyond Diabetes
- Finerenone Across the Stages of Heart Failure: From Prevention to Treatment
- Panel Discussion and Q&A – Cardio-Renal Protection in CKM Diseases
- Digital Health Technologies for Cardiometabolic Disease & Diabetes
- Food Is Medicine Strategies for Nutrition Security & Cardiometabolic Health Equity
- Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes
- Racial Differences in Diabetic Cardiomyopathy: Results From the ARISE-HF Study
- Panel Discussion and Q&A – JACC
- Technology in the Management of Diabetes: Addressing Its Role in Comorbidities
- SGLT2 Inhibitors: Reconsidering, Repurposing, Reimagining
- Panel Discussion and Q&A – Diabetes Management & Technology
Day 3 sessions 17 videos
- Management of Complex Cases: Obesity and Heart Failure
- The Edema Dilemma – A Case of Diabetes Mellitus, HFpEF, Obesity, CKD and Proteinuria
- CRM Management of Complex Cases
- The Lancet Commission on Obesity
- Obesity: Role of Medical Management
- Management of Obesity Addressing Lean Mass Preservation
- Panel Discussion and Q&A – Obesity
- Do ACEI/ARB Still Have a Role in the Era of SGLT2, MRA and GLP1A?
- The Role of Diastolic & Pulse Pressure in CKD & CVD – Management Considerations
- Aldosterone: The Forgotten Hormone in Hypertension
- Panel Discussion and Q&A – The Kidney and Hypertension
- Combination Treatment to Improve Heart and Kidney Outcomes in Diabetic Kidney Disease
- The Latest Heart Disease & Stroke Statistics: US & Global Data from the American Heart Association
- Appropriate Cardiac Intervention in the Diabetes Cardiorenal & Metabolic Medicine Patient
- Serum Lipoproteins & Coronary Atherosclerosis in Asymptomatic U.S. Adults Without Traditional Risk Factors
- Cardiovascular Outcome Trials Update
- Panel Discussion and Q&A – ASCVD
Before you buy
Are slides or PDFs included?
No — the course is supplied as 72 MP4 videos without PDF handouts.
Is it only for diabetes specialists?
No. It is aimed equally at cardiologists, endocrinologists and nephrologists managing patients across the cardio-renal-metabolic spectrum.
Do I get CME credit or a certificate?
No. Clinicapedia provides the educational content only — no CME or CE credits, MOC points or certificates of completion are included with this product.
Specifications
| Format | MP4 video (no PDFs) |
|---|---|
| Contents | 72 videos · about 21 h 51 min |
| Edition | 9th annual conference, 2025 |
| Publisher | Heart in Diabetes |
| Department | Cardiology |
| Delivery | Instant download · lifetime re-download |
Related products
Cardiology
Cardiology
Anesthesiology
